Compare Adaptive Biotechnologies Corp (ADPT) vs Walmart Stores Inc (WMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Walmart Stores Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Walmart Stores Inc trades at $113.24 (market cap $887.64B). The key difference: Walmart Stores Inc is far larger — about 266.6× Adaptive Biotechnologies Corp's market cap, and Walmart Stores Inc pays a 0.89% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WMT | |
|---|---|---|
Market Cap | $3.33B | $887.64B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $134.20 |
52-Week Low | $10.24 | $94.40 |
Enterprise Value | $3.19B | $951.09B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Walmart's stock trades at $110.65, down 1.06% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $681.0B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent news highlights Walmart's AI initiatives and expansion of drone deliveries, while analyst consensus remains strongly bullish with a $141.64 price target.
The outlook is positive given Walmart's consistent earnings beats and strategic investments in technology, though near-term price pressure and competitive threats from Amazon pose risks. The stock offers a compelling entry point for long-term investors seeking defensive exposure with growth potential, supported by solid fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
